mFOLFOX6 + bevacizumab + cetuximab

This regimen is a combination cancer therapy consisting of the mFOLFOX6 chemotherapy protocol plus the monoclonal antibodies bevacizumab and cetuximab. - **mFOLFOX6** includes folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin, administered in cycles for colorectal and other gastrointestinal cancers. Folinic acid enhances 5-FU activity; 5-FU inhibits thymidylate synthase, disrupting DNA synthesis; oxaliplatin forms DNA crosslinks leading to apoptosis[1][4][7]. - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. - **Cetuximab** is a monoclonal antibody targeting epidermal growth factor receptor (EGFR), blocking downstream signaling involved in cell proliferation. This combination targets tumor cells directly via cytotoxic chemotherapy and indirectly by inhibiting tumor blood vessel formation and EGFR-mediated signaling pathways.